CoChat

Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery

Open access
Hampel, Harald, Vergallo, Andrea, Caraci, Filippo, Cuello, A. Claudio, Lemercier, Pablo, Vellas, Bruno, Giudici, Kelly Virecoulon, Baldacci, Filippo, Hänisch, Britta, Haberkamp, Marion, Broich, Karl, Nisticò, Robert, Emanuele, Enzo, Llavero, Francisco, Zugaza, José L., Lucía, Alejandro, Giacobini, Ezio, Lista, Simone · 2021 · Neuropharmacology
Cited by 50

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Abstract

Once first Alzheimer's disease (AD) disease-modifying therapies will become available, global healthcare systems will be challenged by a large-scale demand for clinical and biological screening. Validation and qualification of globally accessible, minimally-invasive, and time-, cost-saving blood-based biomarkers needs to be advanced. Besides established pathophysiological pathways, novel mechanisms (and related candidate biomarkers) - including distinct neuroinflammation pathways (TREM2 and YKL-40), axonal degeneration (neurofilament light chain protein), synaptic dysfunction (neurogranin, synaptotagmin, α-synuclein, and SNAP-25) - may be integrated into an expanding pathophysiological and biomarker matrix and, ultimately, detected and followed-up by comprehensive blood-based liquid biopsy, aligned with the evolving ATN + classification and the precision medicine systems. Liquid biopsy-based diagnostic and therapeutic algorithms are increasingly employed in Oncology disease-modifying therapies and illustrate an enormous potential for AD and other brain diseases as well. Newly identified aberrant molecular pathways have been identified as suitable therapeutic targets and are currently investigated by academia/industry-led R&D programs, including the nerve-growth factor pathway in basal forebrain cholinergic neurons, the sigma1 receptor, and the GTPases of the Rho family. Evidence for a clinical long-term effect on cognitive function and brain health span of cholinergic compounds, drug candidates for repositioning programs, and non-pharmacological multidomain interventions (nutrition, cognitive training, and physical activity) is developing as well. Ultimately, novel pharmacological paradigms, such as quantitative systems pharmacology-based integrative/explorative approaches, are gaining momentum to optimize drug discovery and accomplish effective pathway-based strategies for precision medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2020.108081

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 88 references

Cited by

See all 50

Metadata

Authors
Hampel, H., Vergallo, A., Caraci, F., Cuello, A. C., Lemercier, P., Vellas, B., Giudici, K. V., Baldacci, F., Hänisch, B., Haberkamp, M., Broich, K., Nisticò, R., Emanuele, E., Llavero, F., Zugaza, J. L., Lucía, A., Giacobini, E., & Lista, S.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2021-03
Volume
185
Pages
108081
ISSN
0028-3908 (ISSN-L)
OpenAlex
W3023487221
Cited by
50
References
88
FWCI
4.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. https://app.cochat.ai/papers/10.1016/j.neuropharm.2020.108081
The paper
Hampel, H., Vergallo, A., Caraci, F., Cuello, A. C., Lemercier, P., Vellas, B., Giudici, K. V., Baldacci, F., Hänisch, B., Haberkamp, M., Broich, K., Nisticò, R., Emanuele, E., Llavero, F., Zugaza, J. L., Lucía, A., Giacobini, E., & Lista, S. (2021). Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2020.108081

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.